The tumor cell proliferation marker Ki67 was detected by IHC, and CAY10683 treatment alone did not reduce the proliferating HCC cell ratio in vivo, while administration of CAY10683 and sorafenib distinctly inhibited HCC cell proliferation in sorafenib-sensitive and -resistant CDX models (Fig. 7G). The gene discussed is MKI67; the disease is neoplasm.